18:36 , Aug 23, 2018 |  BC Innovations  |  Emerging Company Profile

Bugs on film

Microbiome company Scioto Biosciences Inc. is turning a longstanding enemy of antibiotics developers -- biofilms -- into a delivery vehicle for probiotics. The company expects its lead candidate SB-121, an orally delivered biofilm formulation of...
21:04 , Jan 27, 2017 |  BC Week In Review  |  Financial News

Allinaire Therapeutics completes venture financing

On Jan. 26, pulmonary disease company Allinaire Therapeutics LLC (Cleveland, Ohio) raised $950,000 in seed financing from BioCrossroads’ Indiana Seed Fund II, BioMotiv and Indiana University’s Innovate Indiana Fund. Allinaire Therapeutics LLC , Cleveland, Ohio ...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Financial News

Assembly completes venture financing

Assembly Pharmaceuticals Inc. , San Francisco, Calif.   Business: Infectious   Date completed: 4/10/14   Type: Venture financing   Raised: Not disclosed.   Investors: Luson Bioventures; BioCrossroads; Johnson & Johnson Development Corp.; Twilight Venture Partners;...
08:00 , Feb 20, 2014 |  BC Innovations  |  Cover Story

Europe's upwelling

SciBX 's third annual comprehensive analysis of public-private partnerships and early stage venture financing activity shows that Europe's public-private partnership activity in 2013 surpassed that of the U.S. in dramatic fashion. At least 314 companies...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Eli Lilly, Roche, Biomet, BioCrossroads, Cook Group, The Dow Chemical Co., Indiana University, Purdue University, University of Notre Dame endocrine/metabolic,

The group of industry partners and research institutions created the non-profit Indiana Biosciences Research Institute to discover and develop health technologies, with an initial focus on cardiovascular disease, diabetes, obesity and nutrition. The state of...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Financial News

Esanex completes venture financing

Esanex Inc. , Indianapolis, Ind.   Business: Cancer   Date completed: 1/10/13   Type: Venture financing   Raised: $15.5 million   Investors: BioCrossroads; Intersouth Partners; Lilly Ventures   Note: Esanex raised $500,000 from BioCrossroads Indiana...
00:59 , Jan 11, 2013 |  BC Extra  |  Financial News

Esanex raises $500,000 from BioCrossroads

Cancer company Esanex Inc. (Indianapolis, Ind.) raised $500,000 from BioCrossroads Indiana Seed Fund II. The funding is part of Esanex's series A round; according to a December SEC filing, the newco has raised $15.5 million...
07:00 , May 7, 2012 |  BC Week In Review  |  Financial News

BioCrossroads financial update

BioCrossroads raised $8.3 million for its Indiana Seed Fund II. The fund will invest an average of $500,000 in early-stage biotech, pharmaceutical, medical device, diagnostic, agricultural-biotech and health IT products and platforms in Indiana. BioCrossroads...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Financial News

INext Fund financial update

The INext Fund launched a $58 million venture capital fund of funds. The fund, which was organized by Indiana's BioCrossroads initiative and will be managed by Credit Suisse, will invest in Indiana's life sciences industry....
08:00 , Dec 21, 2009 |  BioCentury  |  Finance

Ebb & Flow

The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc . (Tokyo:4503) has led to big payoffs in the last two weeks for Calixa Therapeutics Inc. and...